Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 2006;24: 3174–3182.PubMed
Hirsch EC. How to judge animal models of Parkinson’s disease in terms of neuroprotection. J Neural Transm Suppl 2006;70: 255–260.PubMed
Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology 2003;60: 1234–1240.PubMed
Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [Erratum in: Neurology. 2006;67:299]. Neurology 2006;66: 976–982.PubMed
Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson’s disease: an evidence-based review. Mov Disorders 2002;17 Suppl 4: S1-S166 (abstracts).
Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disorders 2005;20: 523–529.
Fearnley J, Lees AJ. Aging and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114: 2283–2301.PubMed
Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989;46: 1052–1060.
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989;321: 1364–1371.
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328: 176–183.
Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. Biofactors 1999;9: 267–272.PubMed
Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001;49: 561–574.PubMed
Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 2007;82: 1–27.PubMed
Deutch AY. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease. J Neural Transm Suppl 2006;70: 67–70.PubMed
Zigmond MJ. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism Neurobiol Dis 1997;4: 247–253.
Fahn S, Oakes D, Shoulson I, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351: 2498–2508.PubMed
Fahn S, Elton RL; Members of the UPDRS Development Committee. Unified Parkinson Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson’s disease. Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987: 153–164.
Shults CW, Oakes D, Kieburtz K, et al.; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson’s disease: evidence for slowing of the functional decline. Arch Neurol 2002;59: 1541–1550.PubMed
Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC. Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials. Clin Trials 2005;2: 509–518.PubMed
Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22: 41–47.PubMed
Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64: 208–215.PubMed
Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson’s disease progression? Eur J Neurol 2002;9 Suppl 3: 15–22.PubMed
Schillaci O, Pierantozzi M, Filippi L, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123
I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging 2005;32: 1452–1456.PubMed
Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol 2007;6: 926–932.PubMed
Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson’s disease. Brain 2007;130: 1834–1846.PubMed
Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson’s disease neuroprotection futility studies. Ann Neurol 2005;57: 197–203.PubMed
Peterson AL, Nutt JG. Treatment of Parkinson’s disease with trophic factors. Neurotherapeutics 2008;5: 270–280.PubMed
Spencer JP, Jenner A, Butler J, et al. Evaluation of the prooxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson’s disease. Free Radic Res 1996; 24: 95–105.PubMed
Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003;53 Suppl 3: S26-S38.PubMed
Heikkila RE, Terleckyj I, Sieber BA. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. J Neural Transm Suppl 1990;32: 217–227.PubMed
Giladi N, McDermott MP, Fahn S, et al.; the Parkinson Study Group. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001;56: 1712–1721.PubMed
Djaldetti R, Ziv I, Melamed E. The effect of deprenyl washout in patients with long-standing Parkinson’s disease. J Neural Transm 2002;109: 797–803.PubMed
LeWitt PA, Oakes D, Cui L; Parkinson Study Group. The need for levodopa as an endpoint of Parkinson’s disease progression in a clinical trial of selegiline and α-tocopherol. Mov Disord 1997; 12: 183–189.PubMed
Ward CD. Does selegiline delay progression of Parkinson’s disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57: 217–220.PubMed
Mäki-Ikola O, Heinonen E. Study design problems of DATATOP study analysis. Ann Neurol 1986;40: 946–948.
Tetrud JW, Langsten JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989;245: 519–522.PubMed
Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as a primary treatment of Parkinson’s disease. Acta Neurol Scand Suppl 1991;136: 70–72.PubMed
Pålhagen S, Heinonen EH, Hägglund J, et al.; Swedish Parkinson Study Group. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 1998;51: 520–525.PubMed
Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson’s disease. Neurology 2006;66: 1200–1206.PubMed
Larsen JP, Boas J, Erdal JE; The Norwegian-Danish Study Group. Does selegiline modify the progression of early Parkinson’s disease? Results from a five-year study Eur J Neurol 1999; 6: 539–547.
Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003;110: 509–515.PubMed
Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson’s disease. Arch Neurol 1994;51: 342–347.
LeWitt PA, Segel SA, Mistura KL, Schork MA. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clin Neuropharmacol 1993;16: 332–337.PubMed
Parkinson Study Group. Effect of lazabemide on the progression of imaging in early Parkinson disease. Ann Neurol 1996;40: 99–107.
Akao Y, Youdim MB, Davis BA, Naoi M, Rabey JM. Rasagiline mesylate, a new MAO B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. J Neurochem 2001;78: 727–735.PubMed
Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002; 24: 675–682.PubMed
Mandel S, Grunblatt E, Riederer P, et al. Neuroprotective strategies in Parkinson’s disease: an update on progress. CNS Drugs 2003;17: 729–762.PubMed
Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M. Amyloid processing and signal transduction properties of anti-Parkinson-anti-Alzheimer neuroprotective drugs rasagiline and TV3326. Ann N Y Acad Sci 2003;993: 378–386.PubMed
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease: the TEMPO Study. Arch Neurol 2002;59: 1937–1943.
Carlile GW, Chalmers-Redman RME, Tatton NA, et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric gluteraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000;57: 2–12.PubMed
Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67 Suppl 2: S24-S29.PubMed
Olanow CW, Schapira AH, LeWitt PA, et al. TCH346 as a neuroprotective drug in Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5: 1013–1020.PubMed
Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000;23: 34–44.
Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease. JAMA 2000;284: 1931–1938.
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287: 1653–1661.
Whone AL, Watts RL, Stoessl AJ, et al.; REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54: 93–101.PubMed
Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006;21: 343–353.PubMed
Feiten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats. Neurobiol Aging 1992;13: 339–351.
Feiger B, Teismann P, Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res 2000;883: 216–223.
Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drugs Aging 2001;18: 389–396.PubMed
Hall ED, Andrus PK, Oostveen JA, et al. Neuroprotective effects of pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Mov Disord 1996;11 Suppl 1: 191 (abstract).
Vu TQ, Ling ZD, Ma SY, et al. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. J Neural Transm 2000;107: 159–176.PubMed
Sethi VH, Wu H, Oostveen JA. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 1997;754: 181–186.
Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 1998;71: 295–301.PubMed
Kitamura Y, Kosaka T, Kakimura JI, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1998;54: 1046–1054.PubMed
Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 2000;281: 167–170.PubMed
Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 2000;107: 1165–1173.PubMed
Carvey P, Pieri S, Ling Z. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997;104: 209–228.PubMed
Ling ZD, Robie HC, Tong CW, Carvey PM. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther 1999;289: 202–210.PubMed
Anderson DW, Neavin T, Smith JA, Schneider JS. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 2001;905: 44–53.PubMed
Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP Jr. Inhibition by R(+) or S(−) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 2002;67: 494–500.PubMed
Takata K, Kitamura Y, Kakimura J, Kohno Y, Taniguchi T. Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res 2000;872: 236–241.PubMed
Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, Ogawa N. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res 2001;26: 31–36.PubMed
Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp Neurol 2003;184 Suppl 1: S68-S79.PubMed
Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson’s disease in patients started on ropinirole or L-dopa: an 18
F-dopa PET study. J Neural Transm 2002; 109: 1433–1443.PubMed
LeWitt P, Aizenman E, Newcomer T, Loeffler D; Parkinson Study Group. The search for an endogenous neurotoxin in Parkinson’s disease: TOPA and TOPA-quinone. Mov Disord 1994; 9: 482 (abstract).
Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, Daya S. L-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 2005;1063: 180–186.PubMed
Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord 2004; 19: 997–1005.PubMed
Camp DM, Loeffler DA, LeWitt PA. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem 2000;74: 1229–1240.PubMed
Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson’s disease: external validation by clinical trial simulation. Pharm Res 2007;24: 791–802.PubMed
Fahn S. A pilot trial of high-dose α-tocopherol and ascorbate in early Parkinson’s disease. Ann Neurol 1992;32 Suppl: S128-S132.PubMed
Canet-Avilés RM, Wilson MA, Miller DW, et al. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 2004;101: 9103–9108.PubMed
The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68: 20–28.
Cleren C, Yang L, Lorenzo B, et al. Therapeutic effects of Coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of parkinsonism. J Neurochem 2007 Dec 8 [Epub ahead of print].
Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157: 142–149.PubMed
Constantinescu R, McDermott MP, Dicenzo R, et al. A randomized study of the bioavailability of different formulations of coenzyme Q10 (ubiquinone). J Clin Pharmacol 2007;47: 1580–1586.PubMed
Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson’s disease. Neurology 2007;69: 1480–1490.
The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66: 664–671.
Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006;67: 1262–1264.PubMed
Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recent clinical failures in Parkinson’s disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006;72: 1197–1206.PubMed
Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci U S A 2001;98: 14669–14674.PubMed
Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22: 1763–1771.PubMed
He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001;909: 187–193.PubMed
Diguet E, Fernagut PO, Wei X, et al. Deleterious effects of minocycline in animal models of Parkinson’s disease and Huntington’s disease. Eur J Neurosci 2004;19: 3266–3276.PubMed
Ishitani R, Kimura M, Sunaga K, Katsube N, Tanaka M, Chuang DM. An antisense oligonucleotide to glyceraldehyde-3-phosphate-dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 1996;278: 447–454.PubMed
Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang DM. Evidence that glyceraldehyde-3-phosphate-dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 1996;66: 928–935.PubMed
Kragten E, Lalande I, Zimmermann K, et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(−)-deprenyl. J Biol Chem 1998; 273: 5821–5828.PubMed
Andringa G, Cools AR. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson’s disease, the bilaterally MPTP-treated rhesus monkey. J Neural Transm Suppl 2000;60: 215–225.PubMed
Maroney AC, Glicksman MA, Basma AN, et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 1998;18: 104–111.PubMed
Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 2004;62: 330–332.
Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–622.PubMed
Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science 2003;302: 819–822.PubMed
Rascol O, Olanow CW, Brooks D, et al. A 2-year multicenter placebo-controlled, double blind parallel group study of the effect of riluzole in Parkinson’s disease. Mov Disord 2002;17 (Suppl 5): 39 (abstract).
Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 2002;8: 271–276.PubMed
Vatassery GT, Fahn S, Kuskowski MA; Parkinson Study Group. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology 1998;50: 1900–1902.PubMed
Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson’s disease. Arch Neurol 1995;52: 237–245.
Carlsson T, Björklund T, Kirik D. Restoration of the striatal dopamine synthesis for Parkinson’s disease: viral vector-mediated enzyme replacement strategy. Curr Gene Ther 2007;7: 109–120.PubMed
Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007;22: 1124–1132.PubMed
Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease. Mol Ther 2007;15: 62–68.PubMed
Xue YQ, Zhao LR, Guo WP, Duan WM. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson’s disease. Neuroscience 2007;146: 1245–1258.PubMed
Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson’s disease [Erratum in: Hum Gene Ther 2005;16:400]. Hum Gene Ther 2005; 16: 262–270.PubMed
Mochizuki H. Gene therapy for Parkinson’s disease. Expert Rev Neurother 2007;7: 957–960.PubMed
Ren Y, Liu W, Jiang H, Jiang Q, Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 2005;280: 34105–34112.PubMed
Hunter RL, Dragicevic N, Seifert K, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007;100: 1375–1386.PubMed
Chen H, Zhang SM, Hemán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60: 1059–1064.PubMed
Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A 2004;101: 9435–9440.PubMed
Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A
receptor blockade in experimental models of Parkinson’s disease. J Neurochem 2002;80: 262–270.PubMed